Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305

References

• Augustin E, Moś-Rompa A, Skwarska A, et al. (2006). Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305. Biochem Pharmacol 72:1668–79
   PubMed Web of Science ®Google Scholar
• Bibi Z. (2008). Role of cytochrome P450 in drug interactions. Nutr Metab (Lond) 5:27. DOI: 10.1186/1743-7075-5-27
   PubMed Web of Science ®Google Scholar
• Chang TK, Chen J, Lee WB. (2001). Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 299:874–82
   PubMed Web of Science ®Google Scholar
• Chen Q, Ngui JS, Doss GA, et al. (2002). Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907–14
   PubMed Web of Science ®Google Scholar
• Cholody WM, Martelli S, Konopa J. (1990a). 8-Substitued 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity. J Med Chem 33:2852–6
   PubMed Web of Science ®Google Scholar
• De Groot MJ, Ekins S. (2002). Pharmacophore modeling of cytochromes P450. Adv Drug Deliv Rev 54:367–83
   PubMed Web of Science ®Google Scholar
• Dziegielewski J, Konopa J. (1996). Interstrand crosslinking of DNA induced in tumor cells by a new group of antitumor imidazoacridinones. Proc Am Assoc Cancer Res 37:410 (Abstract)
   Google Scholar
• Dziegielewski J, Slusarski B, Konitz A, et al. (2002). Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem Pharmacol 63:1653–62
   PubMed Web of Science ®Google Scholar
• Ekins S, Kortagere S, Iyer M, et al. (2009). Challenges predicting ligand–receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol 5:1–37
   Web of Science ®Google Scholar
• Fedejko-Kap B, Niemira M, Radominska-Pandya A, Mazerska Z. (2011). Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells. Xenobiotica 41:1044–55
   PubMed Web of Science ®Google Scholar
• Fedejko-Kap B, Bratton SM, Finel M, et al. (2012). The role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10. Drug Metab Dispos 40:1736–43
   PubMed Web of Science ®Google Scholar
• Fontana E, Dansette PM, Poli SM. (2005). Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413–54
   PubMed Web of Science ®Google Scholar
• Foo WY, Tay HY, Chan EC, Lau AJ. (2015). Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A. Biochem Pharmacol 97:320–30
   PubMed Web of Science ®Google Scholar
• Grimm SW, Dyroff MC. (1997). Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 25:598–602
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1995). Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450 structure mechanism and biochemistry. New York, NY: 2nd ed. Plenum Press, 473–535
   Google Scholar
• Guengerich FP. (1999). Cytochrome P450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17
   PubMed Web of Science ®Google Scholar
• Hanioka N, Ozawa S, Jinno H, et al. (2002). Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos 30:391–6
   PubMed Web of Science ®Google Scholar
• Hollenberg PF, Kent UM, Bumpus NN. (2008). Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 21:189–205
   PubMed Web of Science ®Google Scholar
• Hosea NA, Miller GP, Guengerich FP. (2000). Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929–39
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Obach RS, Maurer TS. (2007). Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407–47
   PubMed Web of Science ®Google Scholar
• Kent UM, Roberts ES, Chun J, et al. (1998). Inactivation of cytochrome P450 2E1 by tert-butylisothiocyanate. Chem Res Toxicol 11:1154–61
   PubMed Web of Science ®Google Scholar
• Kitz R, Wilson IB. (1962). Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245–9
   PubMed Web of Science ®Google Scholar
• Kivisto KT, Kroemer HK, Eichelbaum M. (1995). The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523–30
   PubMed Web of Science ®Google Scholar
• Koba M, Konopa J. (2007). Interactions of antitumor triazoloacridinones with DNA. Acta Biochim Pol 54:297–306
   PubMed Web of Science ®Google Scholar
• Kusnierczyk H, Cholody WM, Paradziej-Lukowicz J, et al. (1994). Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch Immunol Ther Exp (Warsz) 42:415–23
   PubMedGoogle Scholar
• Lemke K, Wojciechowski M, Laine W, et al. (2005). Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities. Nucleic Acids Res 33:6034–47
   PubMed Web of Science ®Google Scholar
• Luo G, Cunningham M, Kim S, et al. (2002). CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795–804
   PubMed Web of Science ®Google Scholar
• Macherey AC, Dansette PM. (2008). Biotransformations leading to toxic metabolites: chemical aspect. In: Wermuth CG, ed. The Practice of Medicinal Chemistry. Oxford (UK): Academic Press, 674–96
   Google Scholar
• Masubuchi Y, Horie T. (1999). Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem Res Toxicol 12:1028–32
   PubMed Web of Science ®Google Scholar
• Murray M, Murray K. (2003). Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. Xenobiotica 10:973–87
   Web of Science ®Google Scholar
• Niemira M, Dastych J, Mazerska Z. (2013). Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia. Biochem Pharmacol 86:231–41
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Correia MA. (1995). Inhibition of cytochrome P450. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure, Mechanism and Biochemistry. New York (NY): Plenum Press, 305–66
   Google Scholar
• Pawlowska M, Chu R, Fedejko-Kap B, et al. (2012). Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use. Drug Metab Dispos 41:414–21
   PubMed Web of Science ®Google Scholar
• Richter T, Schwab M, Eichelbaum M, Zanger UM. (2005). Inhibition of human CYP2B6 by N, N′, N″-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem Pharmacol 69:517–24
   PubMed Web of Science ®Google Scholar
• Sevrioukova IF, Poulos TL. (2013). Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans 42:3116–26
   PubMed Web of Science ®Google Scholar
• Silverman RB. (1996). Mechanism-based enzyme inactivation. In: Purich DL, ed. Contemporary enzyme kinetics and mechanisms. San Diego (CA): Academic Press, 291–335
   Google Scholar
• Skladanowski A, Plisov SY, Konopa J, Larsen AK. (1996). Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 49:772–80
   PubMed Web of Science ®Google Scholar
• Sridar C, Kent UM, Notley LM, et al. (2002). Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 301:945–52
   PubMed Web of Science ®Google Scholar
• Stresser DM, Broudy MI, Ho T, et al. (2004). Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32:105–12
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 37:1225–56
   PubMed Web of Science ®Google Scholar
• Voorman RL, Maio SM, Hauer MJ, et al. (1998). Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 26:631–9
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Mimura M, et al. (1996). 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem Pharmacol 51:313–19
   PubMed Web of Science ®Google Scholar
• Yuan R, Madani S, Wei XX, et al. (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–19
   PubMed Web of Science ®Google Scholar
• Zhao XJ, Jones DR, Wang YH, et al. (2002). Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 32:863–78
   PubMed Web of Science ®Google Scholar